Last reviewed · How we verify
Vancocin — Competitive Intelligence Brief
marketed
Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase
Infectious Disease
Live · refreshed every 30 min
Target snapshot
Vancocin (vancomycin) — ANI Pharmaceuticals.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vancocin TARGET | vancomycin | ANI Pharmaceuticals | marketed | Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Vancocin · 11517609 · Method of Use · US
- — Vancocin · 10188697 · Formulation · US
- — Vancocin · 10039804 · Formulation · US
- — Vancocin · 10849956 · Formulation · US
- — Vancocin · 11000567 · Formulation · US
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Vancocin — Competitive Intelligence Brief. https://druglandscape.com/ci/vancomycin. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab